-
Mashup Score: 12
On April 22, 2024, the EC granted approval to cilta-cel for the treatment of RRMM after one or more prior therapies, including an IMiD or PI, who are lenalidomide-refractory with disease progression on the last therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Antigen escape as a mechanism of resistance to T-cell-engaging therapies in multiple myeloma - 4 day(s) ago
Here, we summarize a presentation by Paola Neri on the mechanisms of antigen escape after T-cell-redirecting therapies, presented at the 5th Immune Effector Cell Therapies in Multiple Myeloma Workshop.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy? - 8 day(s) ago
The Multiple Myeloma Hub and Lymphoma Hub were pleased to speak to Anna Sureda, Catalan Institute of Oncology, Barcelona, ES. We asked, What is the rationale for monitoring secondary malignancies after BCMA and CD19 CAR T-cell therapy?
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 23Symposium | BCMA-directed bispecific antibodies - 9 day(s) ago
During the Multiple Myeloma Hub virtual symposium, Naresh Bumma, The Ohio State University, Columbus, US, delivered a presentation on BCMA-directed bispecific antibodies in MM.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 20
Here, we summarize a publication by Mohty et al. in the British Journal of Haematology on patient-reported outcomes following treatment with elranatamab in the phase II MagnetisMM-3 clinical trial.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
Here, we summarize a subanalysis by Oriol et al. published in Clinical Lymphoma, Myeloma and Leukemia on the results of the OPTIMISMM trial by frailty status and bortezomib dose adjustment.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 40
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13Infections following bispecific antibody therapy in MM: incidence and characteristics - 18 day(s) ago
Here, we summarize a multicenter, retrospective study conducted in France on the incidence and characteristics of infections following treatment with bispecific antibody therapy.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Here, we summarize a publication by Murugappan, et al. in Journal of Geriatric Oncology on a comparison between approaches to measuring frailty: the patient-reported frailty phenotype (PRFP) and the International Myeloma Working Group Frailty Index (IMWG FI).
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 41
The Multiple Myeloma Hub virtual symposium was chaired by Sagar Lonial, and featured expert presentations from Naresh Bumma, Amrita Krishnan, and Sergio Giralt.
Source: multiplemyelomahub.comCategories: General Medicine News, Onc News and JournalsTweet
🚨 NEWS 🚨 @EU_Commission approves cilta-cel for the treatment of relapsed/refractory #MultipleMyeloma after ≥1 prior therapy, including an IMiD or PI, who are lenalidomide-refractory with disease progression on the last therapy. Read more: https://t.co/BUz3NRL77J #Myeloma… https://t.co/jlU26eqUMI https://t.co/uzmrCMo348